{"createdAt":"8/2/2020, 1:18:26 PM","timestamp":1596388706113,"Company ID number":"119","DMX_ISSUER_NAME":"Walvax Biotechnology Co., Ltd.","DMX_ISSUER_ID":"IID000000002603059","Country of Classification":"CHINA","name":"Walvax Biotechnology Co Ltd ","code":"300142","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"云南沃森生物技术股份有限公司_李云春","group":"board","name":"李云春","title":"董事长,董事","isMale":true,"age":"58","degree":"本科","salary":"107.8万","stockAmount":"4827万","description":"李云春先生,1962年生,预防医学学士学位。中国国籍,无境外永久居留权。李云春先生有近三十年医学生物制品行业技术背景和企业管理经验。云南沃森生物技术股份有限公司董事、董事长、总裁。现任云南沃森生物技术股份有限公司董事、董事长。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_黄镇","group":"board","name":"黄镇","title":"副董事长,董事","isMale":true,"age":"57","degree":"硕士","salary":"481.2万","stockAmount":"1442万","description":"黄镇先生,1963年生,工程硕士,正高级工程师。中国国籍,无境外永久居留权。黄镇先生从事病毒和细菌性疫苗的研发和生产管理工作三十余年,领导和主持完成了7项国家级、20余项省部级科研项目,是享受国务院政府特殊津贴人员,并获得国家“万人计划”-科技创业领军人才荣誉称号。黄镇先生曾任成都生物制品研究所麻疹组组长、新产品开发研究室组长。云南沃森生物技术股份有限公司副总经理、生产总监,现任云南沃森生物技术股份有限公司董事、副总裁、玉溪沃森董事长。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_姜润生","group":"board","name":"姜润生","title":"董事","isMale":true,"age":"63","degree":"博士","salary":"105.4万","stockAmount":"-","description":"姜润生先生,1957年生,教授,博士生导师。中国国籍,无境外永久居留权。姜润生先生曾任昆明医学院团委书记、院长办公室主任、院长助理、副院长、院长,昆明医科大学校长,云南省人大常委会教科文卫工作委员会副主任。历任教育部高等学校教学指导委员会全科医学教学指导委员会委员,中国高等教育学会医学教育分会常务理事,中华医学会第二十四届理事会理事,中国医师学会全科医师分会第二届常务理事,中华预防医学会社会医学分会第六届常务委员,中华医学会云南省分会副会长,中国医师协会云南省分会副会长,云南省高等教育学会医学教育分会第一、二届理事长,云南省卫生科技教育管理协会第二届协会会长。现任云南沃森生物技术股份有限公司总裁。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_张建生","group":"board","name":"张建生","title":"董事","isMale":true,"age":"47","degree":"本科","salary":"0.00","stockAmount":"-","description":"张建生先生,1973年生,大学学历,高级会计师。中国国籍,无境外永久居留权。张建生先生曾任中轻依兰集团有限责任公司会计、会计主管,云南龙润药业有限公司会计主管,云南龙发制药有限公司综合管理部经理、总经办主任,云南省国有资产经营有限责任公司会计,云南省工业投资控股集团有限责任公司财务管理部副总经理、财务管理部总经理、投资管理部总经理,云南沃森生物技术股份有限公司副总裁。现任云南省投融资担保有限公司董事长、云南沃森生物技术股份有限公司董事。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_钟彬","group":"board","name":"钟彬","title":"独立董事","isMale":true,"age":"48","degree":"大专","salary":"3.980万","stockAmount":"-","description":"钟彬先生,1972年生,四川大学哲学系毕业。中国国籍。曾任全国工商联房地产商会传媒中心主任,全国工商联房地产商会设计专业委员会秘书长,商会常务副秘书长、执行秘书长、秘书长,全联房地产商会秘书长、商会金融工作委员会联席秘书长,云南城投独立董事。现任当代置业、三盛控股独立董事。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_黄伟民","group":"board","name":"黄伟民","title":"独立董事","isMale":true,"age":"57","degree":"硕士","salary":"10.20万","stockAmount":"-","description":"黄伟民先生,1963年生,硕士研究生,中国国籍,国浩律师(北京)事务所合伙人、执业律师。曾任航天晨光、航天通信、北京京运通科技股份公司、海南珠江控股股份有限公司、云南景谷林业股份有限公司独立董事。现任新华资产管理股份有限公司独立董事、云南沃森生物技术股份有限公司独立董事。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_纳超洪","group":"board","name":"纳超洪","title":"独立董事","isMale":true,"age":"43","degree":"博士","salary":"10.20万","stockAmount":"-","description":"纳超洪,男,1977年5月出生,博士生。全国会计学术领军(后备)人才,财务管理博士,现任云南财经大学会计学院教授、财务研究所所长、云南沃森生物技术股份有限公司独立董事。云南企业发展研究中心副主任,硕士生导师,博士导师组成员。曾任MBA中心副主任,商学院院长助理。曾为中欧国际工商学院兼职研究员(CEIBS),丹麦奥胡斯大学(AarhusU)、中国香港中文大学(CUHK)、复旦大学、上海交大访问学者;曾任职证券经纪与投资分析、外贸公司总经理助理、咨询公司总经理、基金公司投决会委员、上市公司独立董事(300142)。主持国家自然、教育部、省科技规划等多项治理与财务金融相关研究,参与30多个国家级省部级研究项目和企业委托项目,如昆明中铁、华能澜沧江、云南电网、云天化、云南工投、世博旅游等。主要研究集团治理与公司财务、高管激励与薪酬、公司并购、企业社会责任。研究成果在《JournalofEconomicBehaviorandOrganization》,《ManagementandOrganizationReview》,《哈佛商业评论》,《会计研究》等国内外一流刊物发表。曾为多家集团、上市公司、银行、税局等主要讲授公司理财、财务报表分析、公司并购、集团财务管控、公司估值、PE/VC运营等课程。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_唐灵玲","group":"supervisoryCommittee","name":"唐灵玲","title":"监事会主席","isMale":false,"age":"37","degree":"大专","salary":"7.830万","stockAmount":"-","description":"唐灵玲女士,1983年生,大专学历,中国国籍,无境外永久居留权。唐灵玲女士曾任职于公司行政人事部、总经办,现任云南沃森生物技术股份有限公司行政事务部主管、职工代表监事。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_魏爱雪","group":"supervisoryCommittee","name":"魏爱雪","title":"监事","isMale":false,"age":"52","degree":"本科","salary":"0.00","stockAmount":"-","description":"魏爱雪女士,1968年生,本科学历,会计师,资产评估师。中国国籍,无境外永久居留权。魏爱雪女士历任云南光大会计师事务所资产评估部主任、副主任会计师,云南省工业投资控股集团有限责任公司审计监察部副部长、政策法规部副部长、部长。现任云南省工业投资控股集团有限责任公司风险控制部部长、云南沃森生物技术股份有限公司监事、监事会主席。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_时季","group":"supervisoryCommittee","name":"时季","title":"职工监事","isMale":true,"age":"26","degree":"本科","salary":"7.450万","stockAmount":"-","description":"时季先生,1994年生,本科学历,中国国籍,无境外永久居留权。时季先生曾任江苏恒瑞医药股份有限公司四川省区攀枝花市区镇静镇痛组业务经理。现任云南沃森生物技术股份有限公司营销中心市场专员、职工代表监事。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_姜润生","group":"manager","name":"姜润生","title":"总裁","isMale":true,"age":"63","degree":"博士","salary":"105.4万","stockAmount":"-","description":"姜润生先生,1957年生,教授,博士生导师。中国国籍,无境外永久居留权。姜润生先生曾任昆明医学院团委书记、院长办公室主任、院长助理、副院长、院长,昆明医科大学校长,云南省人大常委会教科文卫工作委员会副主任。历任教育部高等学校教学指导委员会全科医学教学指导委员会委员,中国高等教育学会医学教育分会常务理事,中华医学会第二十四届理事会理事,中国医师学会全科医师分会第二届常务理事,中华预防医学会社会医学分会第六届常务委员,中华医学会云南省分会副会长,中国医师协会云南省分会副会长,云南省高等教育学会医学教育分会第一、二届理事长,云南省卫生科技教育管理协会第二届协会会长。现任云南沃森生物技术股份有限公司总裁。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_张荔","group":"manager","name":"张荔","title":"董事会秘书","isMale":false,"age":"43","degree":"硕士","salary":"71.06万","stockAmount":"-","description":"张荔女士,1977年生,工程硕士。中国国籍,无境外永久居留权。张荔女士曾任云南石林风景名胜区管理局副局长、云南城投置业股份有限公司办公室主任及其子公司董事长、云南世博股份有限公司总经理助理、云南世博景区投资管理有限公司副总经理。现任云南沃森生物技术股份有限公司董事会秘书兼董事会办公室主任。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_章建康","group":"manager","name":"章建康","title":"副总裁","isMale":true,"age":"63","degree":"硕士","salary":"--","stockAmount":"-","description":"章建康先生,1957年出生,拥有中欧国际工商学院(CEIBS)工商管理硕士、美国伊利诺伊州Dominican大学医学图书和信息学硕士和复旦大学文学学士学位以及上海市卫生局颁发的公共卫生专业毕业证书,副研究员。中国国籍,无境外永久居留权。章建康先生曾任上海生物制品研究所国际生物制品学杂志编辑、所长办公室主任、所长助理和运营副所长,美国血液技术公司(Haemonetics)中国区首任总经理,美国适宜卫生科技组织(PATH)驻华首席代表和杭州优思达生物技术有限公司首席运营官。现任上海赛伦生物技术股份有限公司独立董事,云南沃森生物技术股份有限公司副总裁。","lastUpdated":"2020-05-30"},{"id":"云南沃森生物技术股份有限公司_周华","group":"manager","name":"周华","title":"财务总监","isMale":false,"age":"53","degree":"硕士","salary":"91.22万","stockAmount":"-","description":"周华女士,1967年生,高级工商管理硕士,高级会计师。中国国籍,无境外永久居留权。周华女士曾任云南天然气化工厂驻成都办事处财务负责人,云南云通房地产开发经营有限公司财务部经理,云天化集团有限责任公司资产财务部副部长,云南云天化石化有限公司财务总监。现任云南沃森生物技术股份有限公司财务总监。","lastUpdated":"2019-08-24"},{"id":"云南沃森生物技术股份有限公司_黄镇","group":"manager","name":"黄镇","title":"技术总监","isMale":true,"age":"57","degree":"硕士","salary":"481.2万","stockAmount":"1442万","description":"黄镇先生,1963年生,工程硕士,正高级工程师。中国国籍,无境外永久居留权。黄镇先生从事病毒和细菌性疫苗的研发和生产管理工作三十余年,领导和主持完成了7项国家级、20余项省部级科研项目,是享受国务院政府特殊津贴人员,并获得国家“万人计划”-科技创业领军人才荣誉称号。黄镇先生曾任成都生物制品研究所麻疹组组长、新产品开发研究室组长。云南沃森生物技术股份有限公司副总经理、生产总监,现任云南沃森生物技术股份有限公司董事、副总裁、玉溪沃森董事长。","lastUpdated":"2019-08-13"},{"id":"云南沃森生物技术股份有限公司_袁琳","group":"manager","name":"袁琳","title":"技术总监","isMale":false,"age":"38","degree":"硕士","salary":"97.25万","stockAmount":"-","description":"袁琳女士,1982年生,硕士研究生,中国国籍,无境外永久居留权。袁琳女士云南沃森生物技术股份有限公司研发中心化学偶联中心副主任、新药注册与临床医学中心副主任、研发管理部经理、注册与临床医学部经理、职工代表监事。现任云南沃森生物技术股份有限公司技术总监。","lastUpdated":"2019-08-24"},{"id":"云南沃森生物技术股份有限公司_吴云燕","group":"manager","name":"吴云燕","title":"运营总监","isMale":false,"age":"38","degree":"硕士","salary":"41.13万","stockAmount":"-","description":"吴云燕女士,1982年生,硕士研究生。中国国籍,无境外永久居留权。吴云燕女士云南沃森生物技术股份有限公司营销中心医学经理、医学市场部经理、医学市场总监。现任云南沃森生物技术股份有限公司运营总监兼总裁助理、总裁办公室主任。","lastUpdated":"2019-08-24"},{"id":"云南沃森生物技术股份有限公司_姚伟","group":"manager","name":"姚伟","title":"营销总监","isMale":true,"age":"48","degree":"硕士","salary":"78.27万","stockAmount":"-","description":"姚伟先生,1972年生,工商管理硕士。中国国籍,无境外永久居留权。姚伟先生曾任职于大连高新生物制药有限公司、北京联合汉信生物技术有限公司;历任大连汉信生物制药有限公司销售部经理、副总经理,山东实杰生物科技股份有限公司总经理。现任云南沃森生物技术股份有限公司营销总监。","lastUpdated":"2019-08-24"},{"id":"云南沃森生物技术股份有限公司_赵金龙","group":"manager","name":"赵金龙","title":"投资总监","isMale":true,"age":"47","degree":"本科","salary":"52.72万","stockAmount":"-","description":"赵金龙先生,1973年生,本科学历。中国国籍,无境外永久居留权。赵金龙先生云南沃森生物技术股份有限公司财务部经理,现任云南沃森生物技术股份有限公司投资总监兼投资发展部经理。","lastUpdated":"2019-08-24"},{"id":"云南沃森生物技术股份有限公司_施競","group":"manager","name":"施競","title":"生产总监","isMale":true,"age":"41","degree":"硕士","salary":"102.6万","stockAmount":"-","description":"施競先生,1979年生,硕士。中国国籍,无境外永久居留权。施競先生云南沃森生物技术股份有限公司研发中心下属发酵中心主任,玉溪沃森生产管理部副经理、总经理助理、副总经理。现任云南沃森生物技术股份有限公司生产总监、子公司玉溪沃森生物技术有限公司总经理。","lastUpdated":"2019-08-24"},{"id":"云南沃森生物技术股份有限公司_公孙青","group":"manager","name":"公孙青","title":"人力资源总监","isMale":true,"age":"54","degree":"本科","salary":"53.80万","stockAmount":"-","description":"公孙青先生,1966年生,本科学历。中国国籍,无境外永久居留权。公孙青先生曾任职于云南航天工业总公司昆明电冰箱厂、云大科技股份有限公司、昆明上成生物技术有限公司。云南沃森生物技术股份有限公司董事会办公室主任、证券事务代表、董事会秘书。现任云南沃森生物技术股份有限公司人力资源总监。","lastUpdated":"2019-08-24"},{"id":"云南沃森生物技术股份有限公司_方国良","group":"manager","name":"方国良","title":"质量总监","isMale":true,"age":"43","degree":"硕士","salary":"67.03万","stockAmount":"-","description":"方国良先生,1977年生,硕士研究生,高级工程师。中国国籍,无境外永久居留权。方国良先生曾任云南汉德生物技术有限公司工艺员、三九集团昆明白马制药有限公司QC经理、QM经理、玉溪沃森生物技术有限公司QA经理、QM经理、总经理助理。现任云南沃森生物技术股份有限公司质量总监、玉溪沃森生物技术有限公司副总经理。","lastUpdated":"2019-10-24"},{"id":"云南沃森生物技术股份有限公司_王子龙","group":"manager","name":"王子龙","title":"BD总监","isMale":true,"age":"57","degree":"硕士","salary":"92.98万","stockAmount":"-","description":"王子龙先生,1963年生,硕士,MBA。美国国籍。王子龙先生曾在加拿大和美国企业从事长达14年的药物研究工作,曾任四川善诺生物医药有限公司副总经理、成都欧林生物科技股份有限公司研究所所长。现任云南沃森生物技术股份有限公司BD总监、上海泽润生物科技有限公司副总裁。","lastUpdated":"2019-10-24"},{"id":"云南沃森生物技术股份有限公司_仝鑫","group":"manager","name":"仝鑫","title":"研发总监","isMale":true,"age":"38","degree":"博士","salary":"70.72万","stockAmount":"1.2万","description":"仝鑫先生,1982年生,博士,中国国籍,无境外永久居留权。仝鑫先生先后任上海泽润生物科技有限公司部门经理、项目负责人;先声药业集团有限公司上海创新中心研发总监,并兼任山东先声生物制药有限公司总工程师、江苏省产业技术研究院转化医学与创新药物技术研究所副所长等职务。现任云南沃森生物技术股份有限公司研发总监。","lastUpdated":"2019-10-24"}],"companyName":"云南沃森生物技术股份有限公司","province":"云南省","englishName":"Walvax Biotechnology Co Ltd","industry":"医药生物 — 生物制品Ⅱ","website":"www.walvax.com","mainBusiness":"人用疫苗产品研发、生产、销售","productsName":["b型流感嗜血杆菌结合疫苗（预充）"],"actualController":"","actualControllerSharePercentage":"","registeredCapital":"15.37亿元","employeeAmount":"1237","phone":"86-0871-68312779","location":"云南省昆明市五华区高新区科园路99号鼎易天城9栋A座19楼","chineseDescription":"云南沃森生物技术股份有限公司是一家专业从事人用疫苗产品研发、生产、销售的生物制药企业.公司主要产品是各类安全有效、品质优异、技术先进的人用疫苗.本公司现拥有一个先进的疫苗中试研发中心,建成了一个现代化疫苗生产基地,构建了一个覆盖全国29个省区、2,000多个县市的营销网络.本公司一直专注于疫苗领域发展,凭借对行业的深刻理解和敏锐的洞察力,确立了以市场需求为导向,以\"产品升级换代\"和\"填补国内空白\"为主的产品研发战略,精心构建了技术领先的研发技术平台和高效的研发管理体系,截至2010年已在13个疫苗产品的开发研制上取得显著的成果,同时储备了一批品种丰富、结构合理且市场前景广阔的产品梯队.本公司自...查看全部▼云南沃森生物技术股份有限公司是一家专业从事人用疫苗产品研发、生产、销售的生物制药企业.公司主要产品是各类安全有效、品质优异、技术先进的人用疫苗.本公司现拥有一个先进的疫苗中试研发中心,建成了一个现代化疫苗生产基地,构建了一个覆盖全国29个省区、2,000多个县市的营销网络.本公司一直专注于疫苗领域发展,凭借对行业的深刻理解和敏锐的洞察力,确立了以市场需求为导向,以\"产品升级换代\"和\"填补国内空白\"为主的产品研发战略,精心构建了技术领先的研发技术平台和高效的研发管理体系,截至2010年已在13个疫苗产品的开发研制上取得显著的成果,同时储备了一批品种丰富、结构合理且市场前景广阔的产品梯队.本公司自主研发、拥有自主知识产权的第一个疫苗Hib及第二个疫苗冻干A、C脑膜炎球菌多糖结合疫苗分别已于2007年9月、2009年9月通过自行产业化成功投产上市,通过积极贯彻本公司确立的以品牌营销为导向、渠道网络覆盖为基础、快速覆盖抢占终端的营销策略,上述两个产品上市以来均取得良好的市场业绩.随着公司后续储备疫苗不断产业化,本公司已成为国内最具有持续成长活力的生物制药企业之一。收起▲","foundedDate":"2001-01-16","goPublicDate":"2010-11-12","companyHistory":"云南沃森生物技术股份有限公司（以下简称本公司或云南沃森，在包含子公司时统称本集团）系经云南省工商行政管理局批准，于2009年6月25日在昆明市成立的股份有限公司，企业法人统一社会信用代码：91530000719480244Y，注册地址：昆明市高新开发区北区云南大学科技园2期A3幢4楼。法定代表人：李云春。\n　　本公司前身系云南沃森生物技术有限公司（以下简称沃森生物有限），成立于2001年1月16日。2009年6月22日，经沃森生物有限股东会决议，全体股东作为股份有限公司的发起人，以其持有的截至2009年5月31日的审定净资产按1:0.9662比例折股，整体变更为股份有限公司。截至2009年5月31日的审定净资产为77,626,523.60元，该净资产折合股本75,000,000.00元，其余部分2,626,523.60元计入资本公积。信永中和会计师事务所为本次变更出具了XYZH/2007SZA2032-2号验资报告，本公司于2009年6月25日完成了工商登记变更手续。\n　　经中国证券监督管理委员会证监许可[2010]1440号批准，本公司于2010年11月1日公开发行人民币普通股2,500万股，并于2010年11月12日在深圳证券交易所上市交易，公开发行后股本总额变更为10,000万股。信永中和会计师事务所为本次变更出具了XYZH/2010SZA2004号验资报告，本公司于2010年12月9日完成了工商登记变更手续。\n　　根据本公司2011年4月25日召开的2010年度股东大会决议，本公司以2010年12月31日的总股本10,000万股为基数,以资本公积金转增股本，每10股转增5股,共计转增股本5,000万股,本次变更后，本公司总股本为15,000万股。\n　　根据本公司2012年4月13日召开的2011年度股东大会决议，本公司以2011年12月31日的总股本15,000万股为基数，以资本公积金转增股本，每10股转增2股，共计转增股本3,000万股。\n　　截至2012年6月30日，本公司总股本为18,000万股。\n　　根据本公司2012年8月14日召开的2012年第一次临时股东大会通过的《云南沃森生物技术股份有限公司限制性股票激励计划（草案修订稿）》以及《关于提请股东大会授权董事会办理股权激励计划有关事项的议案》，2012年9月4日第一届董事会第二十七次会议通过的《关于向激励对象授予限制性股票的议案》和修改后的章程规定，本公司授予黄镇、张翊、徐可仁、王云华等65位高管及核心技术人员限制性股票，向激励对象定向发行人民币普通股股票223.20万股（每股面值1元），授予日为2012年9月4日，变更后的总股本为18,223.20万股。信永中和会计师事务所为本次变更出具了XYZH/2012SZA2004-2号验资报告，本公司于2012年10月23日完成了工商登记变更手续。\n　　根据本公司2013年8月29日召开的2013年第六次临时股东大会决议通过的《关于终止公司限制性股票股权激励计划及回购注销已授予限制性股票的议案》以及《关于公司减少注册资本的议案》和修改后的章程规定，本公司按调整后的回购价格21.41元/股将原授予黄镇、张翊、徐可仁、王云华等65位高管及核心技术人员的尚未获解锁限制性股票，由本公司全部回购注销，同时减少本公司注册资本，变更后的总股本为18,000.00万元。已经信永中和会计师事务所出具了XYZH/2013KMA3011号减资报告。\n　　根据本公司2014年5月6日召开的2013年年度股东大会会议决议通过，本公司以2013年12月31日总股本18,000.00万股为基数，向全体股东以资本公积转增股本，每10股转增3股，共计转增股本5,400.00万股，本次变更后，公司股本为23,400.00万股。\n　　根据本公司2015年4月14日召开的2014年年度股东大会审议通过，本公司以2014年12月31日总股本234,000,000股为基数，向全体股东以资本公积转增股本，每10股转增10股，共计转增股本234,000,000股，本次变更后，本公司总股本为468,000,000股。\n　　根据本公司2015年9月25日召开的公司2015年第三次临时股东大会审议通过，本公司以2015年6月30日总股本468,000,000股为基数，向全体股东以资本公积转增股本，每10股转增20股，共计转增股本936,000,000股，截至2015年12月31日，本公司总股本为1,404,000,000股。\n　　根据本公司2015年11月24日召开的2015年第五次临时股东大会审议通过《关于公司发行股份购买资产并募集配套资金方案的议案》和《<云南沃森生物技术股份有限公司发行股份购买资产并募集配套资金报告书（草案）（修订稿）>及其摘要（修订稿）的议案》，并经中国证券监督管理委员会《关于核准云南沃森生物技术股份有限公司向新余方略知润投资管理中心（有限合伙）发行股份购买资产并募集配套资金的批复》（证监许可（2016）【111】号)，同意公司实施发行股份购买资产并募集配套资金项目。公司向新余方略知润投资管理中心（有限合伙）发行了68,577,982股股票，购买其持有的上海泽润33.53%的股权和嘉和生物15.45%的股权，同时，向前海开源基金管理有限公司、中欧盛世资产管理（上海）有限公司、渤海证券股份有限公司发行了64,859,002股股票，共募集配套资金5.98亿元。公司此次发行股份购买资产并募集配套资金项目合计共发行公司普通股股票133,436,984股。2016年10月14日，上述新发行的133,436,984股公司股票登记上市，公司总股本由1,404,000,000股增加至1,537,436,984股。收起▲","shareholders":[{"organizationId":"T000029056","holderName":"云南省工业投资控股集团有限责任公司","totalShare":"1.07亿","sharePercentage":"6.99%"},{"organizationId":"","holderName":"刘俊辉","totalShare":"8741.78万","sharePercentage":"5.69%"},{"organizationId":"T004908767","holderName":"嘉兴裕保投资合伙企业(有限合伙)-无锡中保嘉沃投资合伙企业(有限合伙)","totalShare":"7687.18万","sharePercentage":"5.00%"},{"organizationId":"T000239178","holderName":"新余方略知润投资管理中心(有限合伙)","totalShare":"6857.80万","sharePercentage":"4.46%"},{"organizationId":"","holderName":"李云春","totalShare":"6435.60万","sharePercentage":"4.19%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"5905.42万","sharePercentage":"3.84%"},{"organizationId":"","holderName":"珠海横琴长乐汇资本管理有限公司-智汇3号私募证券投资基金","totalShare":"3715.74万","sharePercentage":"2.42%"},{"organizationId":"","holderName":"陈尔佳","totalShare":"3047.25万","sharePercentage":"1.98%"},{"organizationId":"","holderName":"杨更","totalShare":"2934.10万","sharePercentage":"1.91%"},{"organizationId":"","holderName":"玉溪高新集团房地产开发有限公司","totalShare":"2403.84万","sharePercentage":"1.56%"}],"englishDescription":"Walvax Biotechnology Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of vaccines, monoclonal antibodies and blood products. The Company鈥檚 main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The Company distributes its products mainly in domestic market.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"1,484.21","Price to sales (ttm)":"117.59","Price to book (mrq)":"25.72","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"0.00","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"2.54","Return on equity (ttm)":"1.83","Income statement":{"Revenue":"1,121.22","Total revenue":"1,121.22","Cost of revenue, total":"236.03","Gross profit":"885.19","Selling/general/admin. expenses, total":"610.98","Research & development":"34.97","Depreciation/amortization":"44.66","Interest exp.(inc.),net-operating, total":"(25.26)","Unusual expense (income)":"3.99","Other operating expenses, total":"(15.76)","Total operating expense":"889.61","Operating income":"231.61","Other, net":"(2.15)","Net income before taxes":"229.46","Provision for income taxes":"35.33","Net income after taxes":"194.14","Minority interest":"(52.16)","Net income before extra. items":"141.97","Net income":"141.97","Income available to com excl extraord":"141.97","Income available to com incl extraord":"141.97","Diluted net income":"141.97","Diluted weighted average shares":"1,537.44","Diluted eps excluding extraord items":"0.09","Dps - common stock primary issue":"0.00","Diluted normalized eps":"0.09","Gain (loss) on sale of assets":"(5.57)"},"Balance sheet":{"Cash":"0.01","Cash & equivalents":"2,362.25","Cash and short term investments":"2,362.26","Accounts receivable - trade, net":"512.84","Total receivables, net":"731.17","Total inventory":"313.05","Prepaid expenses":"18.27","Other current assets, total":"18.97","Total current assets":"3,443.72","Property/plant/equipment, total - gross":"2,008.29","Accumulated depreciation, total":"(520.16)","Property/plant/equipment, total - net":"1,488.13","Goodwill, net":"33.66","Intangibles, net":"1,002.88","Long term investments":"901.72","Other long term assets, total":"147.62","Total assets":"7,017.72","Accounts payable":"276.74","Accrued expenses":"309.50","Notes payable/short term debt":"37.00","Current port. of  lt debt/capital leases":"0.00","Other current liabilities, total":"465.22","Total current liabilities":"1,088.47","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"37.00","Deferred income tax":"40.16","Minority interest":"800.80","Other liabilities, total":"223.14","Total liabilities":"2,152.56","Common stock, total":"1,537.44","Additional paid-in capital":"2,754.54","Retained earnings (accumulated deficit)":"573.19","Total equity":"4,865.16","Total liabilities & shareholders' equity":"7,017.72","Total common shares outstanding":"1,537.44","Tangible book value per share, common eq":"2.49","Capital lease obligations":"180.93"},"Cash flow":{"Cash receipts":"1,061.63","Cash payments":"(552.02)","Cash taxes paid":"(243.24)","Changes in working capital":"(204.35)","Cash from operating activities":"62.02","Capital expenditures":"(351.82)","Other investing cash flow items, total":"544.82","Cash from investing activities":"193.00","Financing cash flow items":"(261.95)","Total cash dividends paid":"(68.68)","Issuance (retirement) of debt, net":"(30.00)","Cash from financing activities":"(360.64)","Foreign exchange effects":"(0.21)","Net change in cash":"(105.83)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"80.86","52 Week High":"80.86","52 Week Low":"24.88","Pricing date":"","10 Day Average Trading Volume":"62.60","Market Capitalization":"124,317.20","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"855.00","Beta":"1.14","1 Day Price Change":"10.00","13 Week Price Return (Daily)":"99.80","26 Week Price Return (Daily)":"186.53","5 Day Price Return (Daily)":"22.89","52 Week Price Return (Daily)":"197.28","Year To Date Price Return (Daily)":"149.26","Month to Date Price Return (Daily)":"54.43","Price Relative to S&P500 (4 Week)":"39.17","Price Relative to S&P500 (13 Week)":"57.08","Price Relative to S&P500 (26 Week)":"124.43","Price Relative to S&P500 (52 Week)":"102.03","Price Relative to S&P500 (YTD)":"90.64"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.09","EPS excl. Extra Items (TTM)":"0.05","EPS Normalized (Annual)":"0.09","Revenue per Share (Annual)":"0.73","Revenue per Share (TTM)":"0.69","Book Value (Per Share Annual)":"3.16","Book Value (Per Share Quarterly)":"3.14","Tangible Book Value (Per Share Annual)":"2.49","Tangible Book Value (Per Share Quarterly)":"2.46","Cash Per Share (Per Share Annual)":"1.54","Cash Per Share (Per Share Quarterly)":"1.39","Cash Flow (Per Share Annual)":"0.20","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.00","Dividends (Per Share TTM)":"0.00","EBITD (Per Share TTM)":"0.08","EPS Basic excl. Extra Items (Annual)":"0.09","EPS Basic excl. Extra Items (TTM)":"0.05","EPS incl. Extra Items (Annual)":"0.09","EPS incl. Extra Items (TTM)":"0.05","Free Cash Flow (Per Share TTM)":"-0.27","Dividend (Per Share 5Y)":"0.01"},"Valuation":{"P/E excl. Extra Items (Annual)":"875.68","P/E excl. Extra Items (TTM)":"1,484.21","P/E Normalized (Annual)":"855.30","Price to sales (Annual)":"110.88","Price to sales (TTM)":"117.59","Price to Tangible Book (Annual)":"32.47","Price to Tangible Book (Quarterly)":"32.89","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"25.55","Price to Book (Quarterly)":"25.72","P/E Basic excl. Extra Items (TTM)":"581.13","P/E excl. Extra Items High (TTM)":"581.13","P/E excl. Extra Items Low (TTM)":"28.07","P/E incl. Extra Items (TTM)":"1,484.21","Net Debt (Interim)":"-2,129.95","Net Debt (Annual)":"-2,325.26","Dividend Yield (5Y)":"0.03","Dividend Yield":"--","Current Dividend Yield (TTM)":"0.00"},"Financial Strength":{"Free Cash Flow (Annual)":"-358.49","Current Ratio (Annual)":"3.16","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"0.00","Quick Ratio (Annual)":"2.88","Total Debt/Total Equity (Annual)":"0.76","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"3.21","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"2.82","Total Debt/Total Equity (Quarterly)":"0.00","Free Cash Flow (TTM)":"-410.83","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"0.00"},"Margins":{"Gross Margin (Annual)":"78.95","Gross Margin (TTM)":"77.95","Net Profit Margin % (Annual)":"17.31","Net Profit Margin (TTM)":"12.03","Operating Margin (Annual)":"20.66","Operating Margin (TTM)":"15.00","Pretax Margin (TTM)":"14.62","Pretax Margin (Annual)":"20.47","Operating Margin (5Y)":"6.40","Pretax Margin (5Y)":"-0.32","Free Operating Cash Flow/Revenue (5Y)":"-47.66","Free Operating Cash Flow/Revenue (TTM)":"-38.86","Gross Margin (5Y)":"63.24","Net Profit Margin (5Y)":"-4.60"},"Management Effectiveness":{"Return on Assets (Annual)":"2.72","Return on Equity (TTM)":"1.83","Return on Average Equity (Annual)":"3.01","Return on Average equity (TTM)":"1.77","Return on Investment (Annual)":"3.83","Return on Investment (TTM)":"2.54","Return on Average Assets (5Y)":"-0.61","Return on Average Equity (5Y)":"-0.70","Return on Investment (5Y)":"-0.94","Asset Turnover (Annual)":"0.16","Asset Turnover (TTM)":"0.15","Inventory Turnover (Annual)":"0.86","Inventory Turnover (TTM)":"0.70","Net Income/Employee (Annual)":"166,926.60","Net Income/Employee (TTM)":"102,770.70","Receivables Turnover (Annual)":"2.36","Receivables Turnover (TTM)":"2.47","Revenue/Employee (Annual)":"964,075.90","Revenue/Employee (TTM)":"854,637.40"},"Growth":{"Revenue Growth (Quarterly YoY)":"-36.34","Revenue Growth Rate (5Y)":"9.29","EPS Growth (Quarterly YoY)":"-146.76","EPS Growth (TTM YoY)":"-92.11","EPS Growth Rate (5Y)":"-2.00","Dividend Growth Rate (3Y)":"--","Revenue Growth (TTM YoY)":"12.76","Revenue Growth (Per Share 5Y)":"7.33","Revenue Growth Rate (3Y)":"23.79","EPS Growth Rate (3Y)":"22.69","Book Value Growth Rate (Per Share 5Y)":"9.04","Tangible Book Value Total Equity CAGR (5Y)":"27.42","Capital Spending growth rate 5 year":"7.91","EBITDA CAGR (5Y)":"--","EBITDA Interim CAGR (5Y)":"--","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"-55.10","Net Profit Margin Growth Rate (5Y)":"5.18"},"Income Statement":{"Revenue (Annual)":"1,121.22","Revenue (TTM)":"1,057.19","EBITD (Annual)":"319.21","EBITD (TTM)":"124.47","Earnings Before Taxes (Annual)":"229.46","Earnings Before Taxes (TTM)":"154.53","Net Income to Common (Annual)":"141.97","Net Income to Common (TTM)":"83.75","Earnings Before Taxes Normalized (Annual)":"233.45","Net Income Available to Common Normalized (Annual)":"145.35","Diluted Normalized EPS excl. Extra Items (TTM)":"0.05"}}}